Pharnext to Present at Rodman & Renshaw 19th Annual Global Investment Conference
September 05 2017 - 10:45AM
Business Wire
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA),
a biopharmaceutical company pioneering a new approach to the
development of innovative drugs based on the combination and
repositioning of known drugs, today announced that company
management will present a corporate overview at the Rodman &
Renshaw 19th Annual Global Investment Conference.
The presentation will take place as follows:
- Date: Tuesday, September 12th,
2017
- Time: 5:30 pm EDT (11:30 pm
CEST)
- Venue: Lotte New York Palace
Hotel in New York, New York
If you are interested in meeting the Pharnext management team
during this event, please send an email to Matthew Shinseki at
matthew@sternir.com.
About PharnextPharnext is an advanced clinical-stage
biopharmaceutical company founded by renowned scientists and
entrepreneurs including Professor Daniel Cohen, a pioneer in modern
genomics. Pharnext has two lead products in clinical development.
PXT3003 is currently in an international Phase 3 trial for the
treatment of Charcot-Marie-Tooth disease type 1A and benefits from
orphan drug status in Europe and the United States. PXT864 has
generated positive Phase 2 results in Alzheimer’s disease. Pharnext
is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The
Company identifies and develops synergic combinations of
repositioned drugs at new optimal lower doses. These PLEODRUG™
offer several key advantages: efficacy, safety and intellectual
property including several product or composition of matter patents
already granted. The Company is supported by a world-class
scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange
in Paris (ISIN code: FR00111911287).For more information, visit
www.pharnext.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170905005711/en/
PharnextXavier Paoli, +33 (0)1 41 09 22 30Chief
Commercial Officercontact@pharnext.comorInvestor Relations
(Europe)MC Services AGAnne Hennecke, +49 211 529252
22anne.hennecke@mc-services.euorMedia Relations
(Europe)ALIZE RPCaroline CarmagnolMargaux Pronost+33 (0)1 44 54
36 64pharnext@alizerp.comorInvestor Relations (U.S.)Stern
Investor Relations, Inc.Matthew Shinseki, +1
212-362-1200matthew@sternir.comorMedia Relations (U.S.)Russo
PartnersTony RussoScott
Santiamotony.russo@russopartnersllc.comscott.santiamo@russopartnersllc.com+1
212-845-4251+1 718-344-5843orFinancial Communication
(France)New CAPEmmanuel Huynh, +33 (0)1 44 71 20
40pharnext@newcap.eu
Pharnext (EU:ALPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharnext (EU:ALPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024